Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial. Diabetes Care 2026;49:257–265
Mann JF, Jeppesen OK, Belmar N, McGuire DK, Buse JB (2026)
Publication Type: Journal article
Publication year: 2026
Journal
Book Volume: 49
Pages Range: e111-e112
Journal Issue: 6
DOI: 10.2337/dci26-0039
Involved external institutions
KfH Kuratorium für Dialyse und Nierentransplantation e.V.
Germany (DE)
Novo Nordisk A/S
Denmark (DK)
University of Texas Southwestern Medical Center (UT Southwestern)
United States (USA) (US)
University of North Carolina at Chapel Hill
United States (USA) (US)
Germany (DE)
Novo Nordisk A/S
Denmark (DK)
University of Texas Southwestern Medical Center (UT Southwestern)
United States (USA) (US)
University of North Carolina at Chapel Hill
United States (USA) (US)
How to cite
APA:
Mann, J.F., Jeppesen, O.K., Belmar, N., McGuire, D.K., & Buse, J.B. (2026). Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial. Diabetes Care 2026;49:257–265. Diabetes Care, 49(6), e111-e112. https://doi.org/10.2337/dci26-0039
MLA:
Mann, Johannes F.E., et al. "Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial. Diabetes Care 2026;49:257–265." Diabetes Care 49.6 (2026): e111-e112.
BibTeX: Download